LCA Consortium

The Pharmaceutical Life-Cycle Assessment Consortium (“Pharma LCA”) came together under the banner of PEG and the Sustainable Markets Initiative (SMI) Health Systems Taskforce.

Pharma LCA Consortium

It was formally launched on November 1st, 2023, and consists of eight members:



The Consortium’s purpose is to facilitate a universal approach to assessing the environmental impact of pharmaceutical products. This should enable pharmaceutical companies and their stakeholders, including payers, to make informed choices about product development and patient care. The Consortium’s outputs will be freely accessible to all pharmaceutical companies and their stakeholders.

The Consortium is working to:


Develop pharmaceutical Product Category Rules to enable robust, comparable product LCAs in pharma;


Improve product inventory data to enable more accurate LCA for pharmaceutical products;


Create a tool to support the implementation of the PCR across the sector and by non-LCA experts;


Engage with stakeholders to support the recognition, acceptance, and uptake of the PCR approach developed.


Establish a sector-wide standard for medicines LCA with NHS England and the British Standards Institution (BSI).



Carnstone Partners Limited provides the Project Management Office (PMO) for the Pharma LCA Consortium.
Please contact Daniel Witte if you would like to learn more.